Maryland Cannabis: 108 Stores, 49% Capture, and the Low-Tax Paradox

Maryland has the lowest excise tax rate of any adult-use market in the dataset at 12%. It also has one of the highest final consumer prices at $9.27/g. The result is 49% legal capture two years into adult-use sales — not because the tax policy failed, but because insufficient retail competition has kept pre-tax pricing double the level of full-capture markets. Maryland got the tax structure right and the density wrong.

Market Overview

Maryland legalized adult-use cannabis under HB 556 in April 2023. First recreational sales launched July 1, 2023, converting the existing medical cannabis infrastructure to dual-use operations. The market is regulated by the Maryland Cannabis Administration (MCA).

Key metrics:

• 108 active dispensaries statewide
• FY2025 revenue: $1.16 billion ($874M adult-use + $289M medical; MCA data dashboard)
• $8.28/g flower (pre-tax, FY2026 YTD)
• 12% excise tax (adult-use only; medical fully exempt)
• ~49% estimated resident capture
• $10.7M revenue per store — highest in the dataset
• Medical patient base declined 38.5% since adult-use launch (140,891 → 86,704)

Flower Pricing

Maryland's pricing data comes from the MCA's monthly sales reports. At $8.28/g pre-tax and $9.27/g all-in, Maryland has the second-highest final consumer price among adult-use markets in the dataset — despite its 12% excise being the lowest of any state that has achieved meaningful legal market scale.

The paradox is in the table. Maryland's 12% tax burden is lower than Oregon's 17–20%, Massachusetts's 17–20%, and Maine's 18.7% — all of which achieve full capture at $3.89–7.57/g out the door. Maryland's tax policy is not the problem. Its $8.28/g pre-tax retail price — more than double Oregon, Colorado, and Massachusetts before a single dollar of tax is applied — is. With black market pricing running $5–7/g in the Mid-Atlantic, legal cannabis in Maryland costs 32–85% more than illegal alternatives.

Tax Structure

• 12% excise tax on adult-use retail sales (reduced from 9% at launch to... actually it launched at 9% and increased; as of July 2025 it's 12%)
• 0% tax on medical cannabis sales — fully exempt
• No additional local cannabis taxes
• Combined effective burden: ~12% adult-use

Maryland's tax structure is among the simplest in the dataset — a single flat excise with full medical exemption. The 12% rate is low enough that tax is not a meaningful contributor to Maryland's price disadvantage. The $8.28/g pre-tax floor is a market maturity problem, not a tax design problem.

Total Addressable Market

Maryland's adult population is approximately 4.7 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 4.7 million adults 21+
• 846,000 estimated regular consumers (18%)
• 309 million grams annual demand

At Maryland's current $8.28/g, the resident TAM is approximately $2.56 billion — but this figure is inflated by early-market pricing. As prices compress toward the competitive baseline seen in mature markets ($3–5/g), the dollar TAM will decline substantially even as grams sold hold steady or grow. Actual FY2025 legal revenue of $1.16B against the $2.56B TAM implies approximately 49% capture — with the remaining 51% flowing through unlicensed channels at $5–7/g.

The consumption math validates the framework: Maryland's OCP data implies approximately 0.65 g/day flower consumption per legal consumer — consistent with the 0.50–0.70 g/day validated floor across every other market studied.

Revenue Trend

Maryland's market is only two full fiscal years old, so a trend table requires context — the market launched July 1, 2023.

Growth is modest but consistent. Maryland is not in decline — it's a two-year-old market still building consumer habits and expanding store count. The more instructive comparison is Massachusetts in 2020–2021, its second and third full years of adult-use sales, when prices were still elevated and capture was still building toward 100%.

The Medical Collapse

Maryland's medical patient base declined 38.5% following adult-use launch — from 140,891 registered patients in December 2023 to 86,704 by November 2025. This is not market contraction; it's rational consumer behavior. Medical registration in Maryland carries an annual cost of approximately $250 in physician certification and registration fees. Once adult-use retail opened, casual medical consumers abandoned the registry and simply pay the 12% excise tax instead — an economically rational trade. The patients who remain are higher-need users for whom the medical tax exemption (0% vs 12%) justifies the registration overhead.

Dispensary Density

Maryland's $10.7M per-store revenue is the highest in the dataset — more than Illinois's oligopoly-protected $7.42M, more than Nevada's tourist-inflated $8.05M. That figure is not evidence of operator efficiency. It is evidence of insufficient competition. When 108 dispensaries serve an estimated 846,000 regular consumers across a state with 4.7 million adults, operators face limited competitive pressure to drive prices toward the market-clearing level.

The geographic distribution compounds the density problem. Maryland's dispensaries cluster heavily in the Baltimore-Washington corridor — Montgomery and Baltimore counties account for 18 stores each while Garrett, Somerset, and Talbot counties have zero. Rural and Eastern Shore residents face local monopolies or long drives, creating the same geographic access advantage for unlicensed dealers that drives California's persistent black market.

Home Cultivation

Maryland permits adults 21+ to cultivate up to two plants per household — the most restrictive home grow allowance among adult-use states in this dataset. At any legal market price level, two plants produce insufficient yield to meaningfully displace retail purchases, and the cultivation rights are narrow enough that they have no measurable effect on market capture in either direction.

What the CHS Literature Missed

Maryland has more directly relevant Cannabis Hyperemesis Syndrome data than any other state in this dataset. The MCA's own patient survey — reported by CNS Maryland in April 2025 — found that approximately 200 respondents, roughly 2% of those surveyed, reported having experienced CHS. The majority said they had never experienced it. The surveyed population is Maryland's registered medical cannabis patients — by definition a heavier-use group than the average adult-use consumer.

The MCA generated that 2% figure from its own regulatory data and still did not include CHS in its consumer-facing BeCannabisSmart health campaign. BeCannabisSmart covers drugged driving, smoke-free spaces, accidental consumption, and youth prevention. CHS appears in none of the campaign's topics, fact sheets, or printable materials — despite the MCA having surveyed for it and published the results.

If CHS affected 17–33% of daily users as some clinical estimates suggest, the MCA's own survey would have returned numbers orders of magnitude higher than 2%. The agency that ran the survey, got the 2% figure from its own patient population, and still excluded CHS from consumer health guidance is doing the most direct possible falsification: Maryland's regulatory body concluded that its own data didn't support population-level CHS warnings.

The Bottom Line

Maryland is the clearest illustration in the dataset that tax rate alone does not determine legal market capture. At 12% excise — the lowest of any adult-use state — Maryland should have among the most competitive consumer pricing in the country. Instead it has among the most expensive, because 108 dispensaries serve a 4.7-million-adult state with insufficient competitive pressure to drive prices toward Oregon and Massachusetts levels.

The market is two years old and still maturing. Price compression is happening — down 9.8% from launch — but the trajectory toward the $4–5/g range that would make legal cannabis unambiguously competitive with the black market will take several more years at the current pace. The mechanism is visible in the per-store revenue figure: $10.7M annually is what artificial scarcity looks like. Massachusetts at $4.07M is what competitive pressure looks like. The path from one to the other runs through more dispensary licenses.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.